Reumatizam, Vol. 64 No. 2, 2017.
Pregledni rad
2017 RECOMMENDATION PROPOSAL OF THE CROATIAN SOCIETY OF RHEUMATOLOGY FOR THE TREATMENT OF ADULTS WITH AXIAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS WITH BIOLOGIC DRUGS AND TARGATED SYNTHETIC DRUGS
Simeon Grazio
Srđan Novak
Nadica Laktašić-Žerjavić
Branimir Anić
Đurđica Babić-Naglić
Frane Grubišić
Nikolina Ljubičić Marković
Dušanka Martinović Kaliterna
Miroslav Mayer
Joško Mitrović
Višnja Prus
Tea Schnurrer-Luke-Vrbanić
Tonko Vlak
Sažetak
Spondyloarthritis (SpA) is a group of infl ammatory rheumatic diseases that shares common etiopathogenetical, radiological, and clinical features. Th ese diseases represent a considerable burden both for the individual patient as well as for society. In the last few years important novelties have been introduced in the classification, diagnosis, and treatment of SpA. Th erefore, the Croatian Society for Rheumatology of the Croatian Medical Association has updated its proposal for the use of biologic drugs (reference or biosimilar) and introduced targeted synthetic drugs in the treatment algorithm for adult patients with SpA. Th e proposed recommendations are largely in accordance with those of
renowned European and other international organizations in this field. We hope that a standardized, comprehensive, and up-to-date approach to the fullfilling criteria, drug selection, monitoring, and outcome evaluation that we applied in the full spectrum of patients with SpA will aid clinicians and other interested parties in reaching optimal treatment
outcomes for these patients.
Ključne riječi
Spondyloarthritis – diagnosis, drug therapy; Arthritis, psoriatic – diagnosis, drug therapy; Severity of illness index; Antirheumatic agents – therapeutic use; Biological products – therapeutic use; Biosimilar pharmaceuticals – therapeutic use; Tumor necrosis factor alpha – antagonists and inhibitors; Interleukin-17 – antagonists and inhibitors; Interleukin-23 – antagonists and inhibitors; Ustekinumab – therapeutic use; Th alidomide – analogs and derivatives, therapeutic use; Molecular targeted therapy; Practice guidelines as topic; Croatia
Hrčak ID:
198810
URI
Datum izdavanja:
29.3.2018.
Posjeta: 2.805 *